Fast Quasi-Optimal Power Flow of Flexible DC Traction Power Systems

This paper proposes a quasi-optimal power flow (OPF) algorithm for flexible DC traction power systems (TPSs). Near-optimal solutions can be solved with high computational efficiency by the proposed quasi-OPF. Unlike conventional OPF utilizing mathematical optimization algorithms, the proposed quasi-OPF adopts analytical mapping from load information to near-optimal solutions, hence considerably accelerating the computation. First, we study the mechanism and physical meaning interpretation of conventional OPF based on a new modeling method and successfully interpret the mechanism of conventional OPF in flexible DC TPSs. Then, the analytical mapping from load information to near-optimal solutions is obtained inspired by the mechanism of conventional OPF, and the quasi-OPF algorithm is designed based on the mapping. Since the mapping is based on simple arithmetic, the quasi-OPF algorithm can solve OPF with much less execution time, achieving subsecond level calculation and a speed-up of 57 times compared to conventional OPF. The effectiveness is verified by mathematical proofs and a case study with Beijing Metro Line 13. It provides an insight into the mechanism and physical meaning of OPF, and is a powerful tool for flexible DC TPSs to analyze the effects of coordinated control, design real-time control strategies, and solve operational problems in planning

Cell cycle-dependent phosphorylation of nucleophosmin and its potential regulation by peptidyl-prolyl cis/trans isomerase

Nucleophosmin (NPM) is a ubiquitously expressed phosphoprotein involved in many cellular processes. Phosphorylation is considered the major regulatory mechanism of the NPM protein, associated with diverse cellular events. In this study, we characterized the phosphorylation status of several physiological phosphorylation sites of NPM, especially the newly confirmed in vivo site threonine 95 (Thr95). NPM-Thr95 exhibits a transient and cell cycle-dependent phosphorylation state compared to several other in vivo phosphorylation sites examined, including Ser4, Thr199 and Thr234/Thr237. In addition, we characterized a functional interaction between NPM and the peptidyl-prolyl isomerase Pin1, which specifically bind to each other during mitosis. The demonstration of this binding represents a novel post-phosphorylation regulatory mechanism for NPM that has not been investigated before. Mutated Pin1 putative binding sites result in defected cell division and reduced number of mitotic cells, suggesting that post-phosphorylation is important for NPM in regulating cell cycle progression

Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine

Chemoresistance is the major impediment for treating pancreatic cancer. Herb-derived compound triptolide (TP) can inhibit proliferation of chemo-resistant pancreatic cancer (CPC) cell lines through multiple mechanisms, which exhibited superior anticancer efficacy compared with gemcitabine. However, toxicity due to non-specific exposure to healthy tissues hindered its clinical translation. Herein we successfully achieved targeting CPC cells and avoiding exposure to healthy tissues for TP by nucleolin-specific aptamer (AS1411) mediated polymeric nanocarrier. We conjugated AS1411 aptamer to carboxy terminated poly(ethylene glycol)–block–poly(d, l-lactide) (HOOC-PEG-PDLLA), then prepared AS1411-PEG-PDLLA micelle loading TP (AS-PPT) through solid dispersion technique. AS-PPT showed more antitumor activity than TP and equivalent specific binding ability with gemcitabine-resistant human pancreatic cancer cell (MIA PaCa-2) to AS1411 aptamer in vitro. Furthermore, we studied the distribution of AS-PPT (Cy3-labed TP) at tissue and cellular levels using biophotonic imaging technology. The results showed AS1411 facilitated TP selectively accumulating in tumor tissues and targeting CPC cells. The lifetime of the MIA PaCa-2 cell-bearing mice administrated with AS-PPT was efficiently prolonged than that of the mice subjected to the clinical anticancer drug Gemzar®in vivo. Such work provides a new strategy for overcoming the drug resistance of pancreatic cancer

Predicting Amyloid-β Positivity in Alzheimer’s Disease: Comprehensive Analysis of Feature Selection and Machine Learning Models for Accurate Identification

To accurately identify individuals at risk of Alzheimer’s disease (AD), it is crucial to develop precise tools for predicting amyloid-β (Aβ) positivity in the brain. We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to analyze 1,377 human subjects. These participants were divided into five groups: cognitive normal (CN), subjective memory complaints (SMC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and confirmed AD. Each group was further divided into ten subgroups based on sex, resulting in a comprehensive analysis. The dataset was used to create and evaluate the performance of 15 machine learning (ML) models. A set of 17 potential predictors was generated by combining variables from different categories, including six demographic factors (such as age), ten measurements (such as ADAS13), and APOE4 status. Through ML-based predictive modeling, several cognitive assessment measures, including ADAS13, demonstrate significant importance in multiple ML models. The highest accuracies in the 10 subgroups were 0.875, 0.892, 0.778, 0.850, 0.771, 0.739, 0.781, 0.791, 0.879, and 0.903, respectively. The collection of ML models consists of practical and valuable risk feature scores that can significantly enhance the identification of individuals who are likely to test positive for Aβ

Self-powered on-line ion concentration monitor in water transportation driven by triboelectric nanogenerator

The final publication is available at Elsevier via https://doi.org/10.1016/j.nanoen.2019.05.029. © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/Ion concentration in water is a key criterion for evaluating water quality. In this work, we developed a self-powered on-line ion concentration monitor in water transportation based on impedance matching effect of triboelectric nanogenerator (TENG). A rotary disc-shaped TENG (RD-TENG) and an ion concentration sensor were fabricated based on the industrial printed circuit board (PCB) technology. Flowing water in the pipeline acts as the energy source to drive the RD-TENG and generate an open-circuit (Voc) of 210 V. The ion concentration sensor exhibits a nearly pure resistance characteristic under the alternating current (AC) signal with the frequency below 500 Hz, corresponding to the rotation speed of 250 rpm for the RD-TENG. The impedance matching relationship between the RD-TENG and the ion concentration sensor was experimentally studied and applied to elucidate the sensing mechanism. Finally, a self-powered sensing system integrated with an alarm circuit was assembled which exhibits excellent responsibility and high sensitivity. The change of ion concentration with only 1 × 10−5 mol/L can light up an alarm LED.Natural Science and Engineering Research CouncilCanada Research ChairsNational Natural Science Foundation of China, no. 61804103National Key R&D Program of China, no. 2017YFA0205002Natural Science Foundation of the Jiangsu Higher Education Institutions of China, no. 18KJA535001, no. 14KJB150020Natural Science Foundation of Jiangsu Province of China, no. BK20170343, no. BK20180242China Postdoctoral Science Foundation, no. 2017M610346Collaborative Innovation Center of Suzhou Nano Science & TechnologyPriority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)111 Projec

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F), and TAF 10 mg (E/C/F/TAF) in HIV-1-infected patients with mild to moderate renal impairment. METHODS: We enrolled virologically suppressed HIV-1-infected subjects with estimated creatinine clearance (CrCl) 30-69 mL/min in a single-arm, open-label study to switch regimens to E/C/F/TAF. The primary endpoint was the change from baseline in glomerular filtration rate estimated using various formulae. This study is registered with ClinicalTrials.gov, number NCT01818596. FINDINGS: We enrolled and treated 242 patients with mean age 58 years, 18% Black, 39% hypertension, 14% diabetes. Through week 48, no significant change in estimated CrCl was observed. Two patients (0.8%) discontinued study drug for decreased creatinine clearance, neither had evidence of renal tubulopathy and both had uncontrolled hypertension. Subjects had significant improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001 for all). Hip and spine bone mineral density significantly increased from baseline to week 48 (mean percent change +1.47 and +2.29, respectively, P < 0.05). Ninety-two percent (222 patients) maintained HIV-1 RNA <50 copies per milliliter at week 48. INTERPRETATION: Switch to E/C/F/TAF was associated with minimal change in GFR. Proteinuria, albuminuria and bone mineral density significantly improved. These data support the efficacy and safety of once daily E/C/F/TAF in HIV+ patients with mild or moderate renal impairment without dose adjustment

Roles of extensins in cotyledon primordium formation and shoot apical meristem activity in Nicotiana tabacum

Extensins are cell wall basic glycoproteins with a polypeptide backbone that is extremely rich in hydroxyproline. In this paper, the function of extensins in embryo development was studied in Nicotiana tabacum. By using Western blot and immunohistochemistry, the extensin JIM20 epitopes were found to express in different developmental stages of embryos, and specifically in the top of the embryo proper (EP) and the suspensor of the late globular embryos. In order to clarify the functions of extensins, a potent hydroxyproline synthesis inhibitor, 3,4-dehydro-L-proline (3,4-DHP), was used in ovule and embryo culture. The results showed that the addition of 3,4-DHP caused abnormal embryos with single, asymmetry and supernumerary cotyledon primordia, and continuous culture led to cotyledon defects in the germinated seedlings. Histological sections showed that the shoot apical meristem (SAM) of the abnormal seedlings was dissimilar from the controls, especially in the seedlings with cup-shaped cotyledons. Furthermore, the vasculature of the abnormal cotyledons was in an out-of-order format and contained at least two main veins. Finally, both the hydroxyproline assay and fluorescent immunolocalization confirmed that 3,4-DHP treatment reduced the level of extensins in the cultured ovules and embryos. These results indicate that extensins may play important roles in the cotyledon primordium formation, SAM activity, and vasculature differentiation during embryo development

Individual Professional Practice in the Company

Import 23/08/2017Cílem této bakalářské práce je popsat absolvování odborné praxe ve firmě HS Interactive s.r.o. Praxe byla zaměřena na vývoj mobilní aplikace pro operační systém Android. Aplikace je mobilním klientem pro sociální síť MatchToMe. V úvodu popisuji důvody, které vedly k výběru odborné praxe. Dále se věnuji úkolům, které mi byly zadány s jejich implementací a postupem řešení problémů, které se objevily při vývoji. Závěr práce je věnován zhodnocení získaných zkušeností a dosažených výsledků.Purpose of this bachelor thesis is to describe a professional practice in company HS Interactive s.r.o. Practice was focused on the development of mobile application for the operating system Android. The application is a mobile client for social network MatchToMe. In the introduction I describe reasons that led to the selection of professional practice. Then I describe tasks that I have been awarded with their implementations and process of solution issues that have emerged during development. The conclusion of thesis is dedicated to the evaluation of the experience gained and the results achieved.440 - Katedra telekomunikační technikyvýborn

Remdesivir for 5 or 10 Days in Patients With Severe Covid-19

Background: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale. Results: In total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P = 0.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P = 0.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%). Conclusions: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.)